Table 1.
Molecular formula and chemical structure of small molecule compounds which do not directly target expanded CUG repeats and alleviate pathogenesis of myotonic dystrophy type 1.
Name | Molecular formula | Structure | Potential mechanism of action |
---|---|---|---|
Pentamidine | C19H24N4O2 | ![]() |
Inhibition of transcription |
Propamidine | C17H20N4O2 | ![]() |
|
Heptamidine | C21H28N4O2 | ![]() |
|
Compound 13 | C18H16N4O | ![]() |
|
Actinomycin D | C62H86N12O16 | ![]() |
|
Phenylbuthazone | C19H20N2O2 | ![]() |
Upregultion of muscleblind-like 1 |
Ketoprofen | C16H14O3 | ![]() |
|
ISOX | C22H30N4O6 | ![]() |
|
Vorinostat | C14H20N2O3 | ![]() |
|
Manumycin A | C31H38N2O7 | ![]() |
Inhibition of H-RAS pathway |
Metformin | C4H11N5 | ![]() |
Modulation of protein kinases |
AICAR | C9H14N4O5 | ![]() |
|
Ro 31-8220 | C25H23N5O2S | ![]() |
|
C16 | C13H8N4OS | ![]() |
|
C51 | C23H21N5 | ![]() |
|
Lithium chloride | LiCl | ![]() |
|
TDZD-8 | C10H10N2O2S | ![]() |
|
6-Bromoindirubin-3′-oxime | C16H10BrN3O2 | ![]() |
|
Harmine | C13H12N2O | ![]() |
Undetermined |